Treatment for myeloid leukaemia of Down syndrome: population‐based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials
Anupama Rao(Great Ormond Street Hospital), David Webb(Royal Hospital for Children), Charles Stiller(University of Oxford), Aengus O’Marcaigh(Children's Health Ireland at Crumlin), Brenda Gibson(Royal Hospital for Children), Ian Hann(Royal Hospital for Children), Keith Wheatley(Cancer Research UK Clinical Trials Unit), Siebold S.N. de Graaf(Royal Hospital for Children), Robert K. Hills(Cancer Research UK Clinical Trials Unit)
Cited by 101
Related Papers
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel
|Blood|2012|575
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized <i>WT1</i> Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
|Journal of Clinical Oncology|2009|434
Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
|Journal of Clinical Oncology|2013|415